Cargando…

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD

INTRODUCTION: Several risk factors for severe COVID-19 specific for patients with inflammatory rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence regarding the influence of different RMD treatments on outcomes of SARS-CoV-2 infection is still poor. METHODS: Data from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regierer, Anne Constanze, Hasseli, Rebecca, Schäfer, Martin, Hoyer, Bimba F, Krause, Andreas, Lorenz, Hanns-Martin, Pfeil, Alexander, Richter, Jutta, Schmeiser, Tim, Schulze-Koops, Hendrik, Strangfeld, Anja, Voll, Reinhard E, Specker, Christof, Mueller-Ladner, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Infections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529615/ https://www.ncbi.nlm.nih.gov/pubmed/34670840 http://dx.doi.org/10.1136/rmdopen-2021-001896

Ejemplares similares

National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD
por: Hasseli, Rebecca, et al.
Publicado: (2020)

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases
por: Hasseli, Rebecca, et al.
Publicado: (2021)

Deutsches Register www.Covid19-Rheuma.de: Statusbericht nach 1 Jahr der Pandemie
por: Hasseli, Rebecca, et al.
Publicado: (2021)

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
por: Hasseli, Rebecca, et al.
Publicado: (2023)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
por: Chen, Jing-Wen, et al.
Publicado: (2022)

A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany
por: Hasseli, Rebecca, et al.
Publicado: (2021)

Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination
por: Specker, Christof, et al.
Publicado: (2021)

Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung
por: Specker, Christof, et al.
Publicado: (2021)

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
por: Manders, Sofie HM, et al.
Publicado: (2015)

P15 JAKi of all trades
por: Watkins, Clara, et al.
Publicado: (2023)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Paternal mitochondria from an rmd-2, rmd-3, rmd-6 triple mutant are properly positioned in the C. elegans zygote
por: Juanico, Iris Y, et al.
Publicado: (2021)

Introducing RMD Open
por: Cutolo, Maurizio, et al.
Publicado: (2015)

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors
por: Burja, Blaž, et al.
Publicado: (2020)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
por: Regierer, Anne Constanze, et al.
Publicado: (2023)

High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex
por: Albrecht, Katinka, et al.
Publicado: (2023)

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
por: Frisell, Thomas, et al.
Publicado: (2018)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

OA20 Combining B cell depletion and JAKi for difficult-to-treat rheumatoid arthritis
por: Lee, Sook Yan, et al.
Publicado: (2023)

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort
por: Truchetet, Marie-Elise, et al.
Publicado: (2022)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

RMD: a rice mutant database for functional analysis of the rice genome
por: Zhang, Jianwei, et al.
Publicado: (2006)

Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie e. V. für die Betreuung von Patienten mit entzündlich rheumatischen Erkrankungen im Rahmen der SARS-CoV-2/COVID-19-Pandemie – Update Juli 2020
por: Schulze-Koops, Hendrik, et al.
Publicado: (2020)

Therapeutic inhibition of proteasomes in systemic lupus erythematosus
por: Hiepe, Falk, et al.
Publicado: (2011)

Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit
por: Metsios, George S., et al.
Publicado: (2021)

RMD86, a thiophene derivative, promotes antinociceptive and antipyretic activities in mice
por: da Cruz, Ryldene Marques Duarte, et al.
Publicado: (2020)

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
por: Strand, Vibeke
Publicado: (2021)

JAKi Salvage Therapy Followed by Curative Cord Blood Transplantation in a XIAP-Deficient Infant with Relapsing HLH
por: Maccari, Maria Elena, et al.
Publicado: (2023)

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
por: Vachhani, Pankit, et al.
Publicado: (2023)

Rice SIAH E3 Ligases Interact with RMD Formin and Affect Plant Morphology
por: Chang, Shuwei, et al.
Publicado: (2022)

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
por: Tony, Hans-Peter, et al.
Publicado: (2011)

Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives
por: Tran, Florian, et al.
Publicado: (2021)

RMD-1, a novel microtubule-associated protein, functions in chromosome segregation in Caenorhabditis elegans
por: Oishi, Kumiko, et al.
Publicado: (2007)

RMD-1, a novel microtubule-associated protein, functions in chromosome segregation in Caenorhabditis elegans
por: Oishi, Kumiko, et al.
Publicado: (2009)

Rice actin binding protein RMD controls crown root angle in response to external phosphate
por: Huang, Guoqiang, et al.
Publicado: (2018)

SARS-CoV-2 & Rheuma: Konsequenzen der SARS-CoV-2-Pandemie für Patienten mit entzündlich rheumatischen Erkrankungen. Ein Vergleich der Handlungsempfehlungen rheumatologischer Fachgesellschaften und Risikobewertung verschiedener antirheumatischer Therapien
por: Leipe, J., et al.
Publicado: (2020)

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices
por: Bansback, Nick, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4q9d6nnce1tj53huh2vsp4iqs0